Report type: Weekly Strategy
Aussie Forest Fires and Japanese Artificial Photosynthesis Technology
Ahead of the signing of the US-China Phase 1 trade deal, the US announced that it would remove the “currency manipulator” label from China, and as a result of expectations on improvements on US-China relations, the Japanese stock market during the week of 14/1 began with strong buying. Since the announcement of financial results of Japanese companies fall between the end of the Sept-Nov period and the beginning of the Oct-Dec period, the latest market developments are not due to Japanese stock-specific factors. Instead, the market was influenced by arbitrage trading between spot and futures trades related to the Nikkei 225 index, and as a result, market developments were affected by stocks with high contributions to the index. On top of that, buying of stocks supplying parts to Apple’s (AAPL) iPhone has continued to be prominent.
The World Meteorological Organization announced on 15/1 that the world’s average temperature in 2019 was the second highest in the history of observations, thereby confirming the progress of global warming. Looking overseas, we see that in Australia, especially in 2019, the average rainfall had been the lowest in the history of observations, with dry air and average temperature having record highs. Coupled with a record heat wave in Dec, conditions for a disaster were ripe. As a result, the wild fires that started in 2019/9 showed no signs of abating, and it had been reported that to date, an area equivalent to 30% of the area of Japan had already been burnt. In addition, it was also reported that the huge cloud of smoke arising from the forest fires had caused breathing difficulties in a large number of patients, while the smoke had actually crossed the oceans to reach New Zealand and the South American continent.
It is said that rising average temperatures increase the frequency of floods and droughts. Both poor water hygiene after floods, and poor sanitation as a result of inability to use water lead to the possibility of epidemics. In Dec last year, pneumonia caused by a new virus infection happened in Wuhan, China, and infected patients had also been found in Japan. With regard to the ASF (African Swine Fever) that happened last year, China had been forced to cull large numbers of pigs. The resulting decline in pork supply had led to price increases and impacted the economy enough to shift the trends in global grain and vegetable oil prices. The US-China Phase 1 trade deal may therefore have been driven in part by the need for China to purchase agricultural products in stable and large quantities.
In Japan, a national project, the “Japan Technological Research Association of Artificial Photosynthetic Chemical Process (ARPChem)”, was launched in 2012 aiming to convert CO2 and water into carbon compounds using sunlight. Executive Officer Setoyama of Mitsubishi Chemical Holdings (4188) is in charge as the project leader. In addition, Toshiba (6502) is also aiming to solve problems using its unique approaches. We can look forward to progress on the part of both parties in the near future.
In the 20/1 issue, we will be covering Hisamitsu Pharmaceutical (4530), Resorttrust (4681), Toyota Tsusho (8015), and Life Corporation (8194).
・Founded in 1847. Manufactures, sells, imports and exports pharmaceuticals and quasi-drugs. “SALONPAS” has been registered as a trademark in more than 100 countries and regions. Focusing on development of patches based on transdermal drug delivery systems.
・For 3Q (Mar-Nov) results of FY2020/2, net sales decreased by 3.4% to 99.078 billion yen compared to the same period the previous year, and operating income increased by 15.4% to 18.417 billion yen. Sales declined due to the impact of generics in the US ethical drug business and intensified competition in the domestic ethical drug business. However, improvements in the cost of sales ratio and decrease in SG&A expenses had contributed to profit growth.
・For its full year plan, net sales is expected to increase by 0.1% to 143.5 billion yen compared to the previous year, and operating income to increase by 2.8% to 22.9 billion yen. Based on its slogan, “Conveying patch treatment culture to the world through patches”, company launched “Haruropi Tape”, a transdermal therapeutic agent for Parkinson’s disease, in Japan in 2019/12. Demand is expected to increase as tremors in limbs due to ageing become a social problem as the population ages. The schizophrenia patch approved in the US will be launched in FY2020.
・Established in 1973 in Nagoya. The company engages in the construction and management of membership hotels and golf courses, the sale of hotel memberships, and the medical business (including the sale of medical memberships and medical consulting).
・For 1H (Apr-Sept) results of FY2020/3 announced on 8/11, net sales increased by 8.9% to 84.197 billion yen compared to the same period the previous year, and operating income increased by 39.9% to 8.501 billion yen. “Laguna Baycourt Club”, which opened in 2019/3, contributed to the operating revenue of the Hotel & Restaurant Operation, and sales of hotel memberships centered on high-margin properties increased both sales and profits.
・For its full year plan, net sales is expected to decrease by 4.5% to 171.4 billion yen compared to the previous year, and operating income to decrease by 15.2% to 16.0 billion yen. On 7/12 last year, Chief Cabinet Secretary Suga announced that the government was aiming to establish 50 world-class hotels for wealthy foreigners in various parts of Japan in order to increase the number of foreign visitors to Japan. In collaboration with its Medical Business, company’s hotel-related business is therefore expected to have the potential to appeal to wealthy foreigners from the perspective of medical tourism.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
